CR8164A - Combinacion quimica y metodo para aumentar la liberacion de la coenzima q10 - Google Patents

Combinacion quimica y metodo para aumentar la liberacion de la coenzima q10

Info

Publication number
CR8164A
CR8164A CR8164A CR8164A CR8164A CR 8164 A CR8164 A CR 8164A CR 8164 A CR8164 A CR 8164A CR 8164 A CR8164 A CR 8164A CR 8164 A CR8164 A CR 8164A
Authority
CR
Costa Rica
Prior art keywords
coenzyme
release
chemical combination
increase
chemical
Prior art date
Application number
CR8164A
Other languages
English (en)
Inventor
Erwin Charles
Original Assignee
Erwin Charles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erwin Charles filed Critical Erwin Charles
Publication of CR8164A publication Critical patent/CR8164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con una combinacion quimica y con un metodo para aumentar la liberacion de la coenzima Q10. La combinacion quimica comprende la coenzima Q10 mezclada con por lo menos un quimico. Por lo menos un quimico incluye un aceite(s) esencial que contiene monoterpeno ciclico que permite que los niveles sin precedentes de la coenzima Q10 se hagan disponibles para la liberacion y absorcion, aumentando la biodisponibilidad, asicomo la superacion de los limites previos.
CR8164A 2003-06-25 2006-01-02 Combinacion quimica y metodo para aumentar la liberacion de la coenzima q10 CR8164A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48278103P 2003-06-25 2003-06-25

Publications (1)

Publication Number Publication Date
CR8164A true CR8164A (es) 2006-10-04

Family

ID=33552011

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8164A CR8164A (es) 2003-06-25 2006-01-02 Combinacion quimica y metodo para aumentar la liberacion de la coenzima q10

Country Status (12)

Country Link
US (1) US8003094B2 (es)
EP (1) EP1635873A2 (es)
JP (1) JP2007521279A (es)
KR (1) KR20060082791A (es)
CN (1) CN1809384A (es)
AU (1) AU2004251774A1 (es)
CA (1) CA2529151A1 (es)
CR (1) CR8164A (es)
IL (1) IL172791A0 (es)
MX (1) MXPA05013857A (es)
RU (1) RU2006101991A (es)
WO (1) WO2005000357A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
CN1953743B (zh) 2004-01-22 2010-12-08 迈阿密大学 局部辅酶q10制剂及其使用方法
WO2007040591A2 (en) * 2005-03-01 2007-04-12 Jarrow Formulas, Inc. A ubiquinone composition and a container for its convenient transport and storage
CA2610152C (en) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20090196861A1 (en) * 2005-11-17 2009-08-06 Bioavailability, Inc. Biocompatible Latent Emulsifiers
US20070184040A1 (en) * 2006-02-06 2007-08-09 Clouatre Dallas L Compositions for delivery of coenzyme Q10
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
CA2977089A1 (en) * 2006-05-02 2007-11-15 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
WO2007140331A2 (en) 2006-05-25 2007-12-06 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
US20110136231A1 (en) 2008-04-11 2011-06-09 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CN102481270A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗肿瘤障碍的方法
US9174065B2 (en) * 2009-10-12 2015-11-03 Kona Medical, Inc. Energetic modulation of nerves
US20120156286A1 (en) * 2010-07-27 2012-06-21 Imagenetix, Inc. Compositions and methods for increased delivery of coenzyme q10
CN101955979A (zh) * 2010-09-27 2011-01-26 浙江工业大学 丁羟甲苯和/或α-亚麻酸作为前体在制备辅酶Q10中的应用
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
ES2394245B2 (es) 2012-11-28 2013-12-16 Universidad De Granada Composición de melatonina o sus derivados con coenzima q10 y su uso contra el envejecimiento de la piel
AU2014251045B2 (en) 2013-04-08 2019-06-13 Berg Llc Treatment of cancer using coenzyme Q10 combination therapies
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
KR20160031717A (ko) * 2014-09-15 2016-03-23 삼성전자주식회사 전면 송풍방식 공기조화장치
EP3324957A1 (en) * 2015-07-20 2018-05-30 Repoceuticals ApS Compositions for improving or maintaining myocardial function
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
EP3634391A4 (en) 2017-05-17 2021-02-24 Berg LLC USE OF COENZYME Q10 FORMULATIONS IN THE TREATMENT AND PREVENTION OF BUBBLE EPIDERMOLYSIS
WO2021010843A1 (en) 2019-07-16 2021-01-21 Donaghys Limited Transdermal solvent system and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3512054A1 (de) * 1985-04-02 1986-10-02 HERMES Fabrik pharmazeutischer Präparate Franz Gradinger Gmbh & Co, 8023 Großhesselohe Pharmazeutische zubereitung
HU201674B (en) * 1987-08-26 1990-12-28 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition suitable for curing autoimmune-type leukoencephalomyelitic diseases e.g. sclerosis multiplex
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US6066327A (en) * 1997-12-17 2000-05-23 Color Access, Inc. Antioxidant mixture
GB9828379D0 (en) * 1998-12-22 1999-02-17 Unilever Plc Skin care composition
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
DE10038640A1 (de) * 2000-07-28 2002-02-14 Steigerwald Arzneimittelwerk Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung
US7182950B2 (en) * 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
US20040092482A1 (en) * 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040228884A1 (en) * 2003-05-15 2004-11-18 Gupta Shyam K. Ion-pair delivery system for cosmetic and pharmaceutical compositions
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine

Also Published As

Publication number Publication date
US8003094B2 (en) 2011-08-23
US20050025756A1 (en) 2005-02-03
RU2006101991A (ru) 2006-06-27
CA2529151A1 (en) 2005-01-06
MXPA05013857A (es) 2006-05-17
KR20060082791A (ko) 2006-07-19
WO2005000357A3 (en) 2006-01-05
JP2007521279A (ja) 2007-08-02
WO2005000357A2 (en) 2005-01-06
AU2004251774A1 (en) 2005-01-06
CN1809384A (zh) 2006-07-26
EP1635873A2 (en) 2006-03-22
IL172791A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
CR8164A (es) Combinacion quimica y metodo para aumentar la liberacion de la coenzima q10
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
CR7995A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas correspondiente metodo de produccion , medicamentos que lo contienen y uso de los mismos
UY28342A1 (es) Nuevos compuestos
CR11017A (es) Anticuerpos anti-robo4 y sus usos
PE20060087A1 (es) Metodo para almacenar multiples recursos de datos en un sistema de archivo de un dispositivo
AR088405A2 (es) Proceso de sombreado y composicion de sombreado que comprende una ftalocianina
CR11123A (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacteriales
CR10307A (es) Anteojos con caracteristicas de union a una mascarilla
BRPI0518030A (pt) compostos de metino e de antraquinona copolimerizáveis e artigos que os contêm
CR9675A (es) Agente desinfectante
AR055768A1 (es) Mezclas de aditivos para articulos agricolas
ATE439869T1 (de) Automatisches radioaktives markierungsverafhren
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
UY28670A1 (es) Arilpirazoles sustituidos
CL2009000216A1 (es) Metodo de voladura adicionalmente mejorado
AR051145A1 (es) Composiciones analgesicas / antipireticas para absorcion potenciada
CL2008000642A1 (es) Metodo para integrar contenidos de interfaz de usuario, desde diferentes espacios de procesos, particionados en una sola interfaz de usuario.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
PA8577601A1 (es) Derivados aldehido de polietilenglicol
ECSP024206A (es) Eteres oxima arilo y heteroarilciclopropilo y su uso como fungicidas
AR049842A1 (es) Sistema de coloracion capilar por oxidacion con alto contenido acuoso
AR087283A1 (es) Proceso para la preparacion de una composicion que comprende peroxodicarbonato de di-(tert-butilciclohexilo), composicion de peroxido y uso de la misma
BRPI0514529A (pt) compostos para tingimento de queratina, composições para tingimento de queratina que contêm estes compostos e uso destas composições
CL2010000029A1 (es) Método para limpiar equipos de elaboración de líquidos que contienen materias orgánicas que comprende poner el equipo en contacto con una solución de un compuesto de peryodado, en que dependiendo de si el valor de ph es inferior o superior a 6 se adiciona una solución de un valor de ph de 6 o superior, o un agente oxidante, respectivamente.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)